Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-03, Stock:ABT, The news for the past five days is as follows:
2018-03-26: NEWS1: Is Pfizer's Best Option Now a Consumer Healthcare Spinoff?.NEWS2: Is Pfizer's Best Option Now a Consumer Healthcare Spinoff?.NEWS3: Is Pfizer&apos;s Best Option Now a Consumer Healthcare Spinoff?.NEWS4: See what the IHS Markit Score report has to say about Abbott Laboratories..
2018-03-27: NEWS1: Analysts’ March 2018 Ratings for Baxter International and Peers.NEWS2: Analysts’ March 2018 Ratings for Baxter International and Peers.NEWS3: What Wall Street Analysts Recommend for Medtronic Stock.NEWS4: What Wall Street Analysts Recommend for Medtronic Stock.NEWS5: A Look at Medtronic’s Technical Indicators.NEWS6: A Look at Medtronic’s Technical Indicators.NEWS7: Trade War Fears Triggered Medtronic’s Stock Decline on March 23.NEWS8: Trade War Fears Triggered Medtronic’s Stock Decline on March 23.NEWS9: Notable ETF Inflow Detected - IWD, ABT, MDT, PNC.NEWS10: Notable ETF Inflow Detected - IWD, ABT, MDT, PNC.
2018-03-28: NEWS1: [$$] Bigfoot Biomedical Adds $18 Million to Series B to Manage Diabetes.NEWS2: [$$] Bigfoot Biomedical Adds $18 Million to Series B to Manage Diabetes.NEWS3: Trade War Fears Grip MedTech:  3 Stocks on the Line of Fire.NEWS4: Trade War Fears Grip MedTech:  3 Stocks on the Line of Fire.NEWS5: Baxter International Created a New Reporting Structure for 2018.NEWS6: Baxter International Created a New Reporting Structure for 2018.NEWS7: Baxter International’s 2018 Revenues Expected to See Modest Rise.NEWS8: Baxter International’s 2018 Revenues Expected to See Modest Rise.NEWS9: It's Not Final 4 But WashU, Wisconsin Fight on Other Court.NEWS10: It's Not Final 4 But WashU, Wisconsin Fight on Other Court.
2018-03-29: NEWS1: What’s behind Omeros’s Cash Flow.NEWS2: What’s behind Omeros’s Cash Flow.NEWS3: Analysts’ Ratings for Omeros and Peers in March 2018.NEWS4: Analysts’ Ratings for Omeros and Peers in March 2018.NEWS5: These medical devices are getting better at treating chronic pain.NEWS6: These medical devices are getting better at treating chronic pain.NEWS7: Sum Up The Pieces: SPLV Could Be Worth $51.NEWS8: Sum Up The Pieces: SPLV Could Be Worth $51.NEWS9: Abbott Initiates Trial to Evaluate Improved Survival And Outcomes with the CardioMEMS Monitor.
2018-04-02: NEWS1: Abbott Starts GUIDE-HF Clinical Trial for CardioMEMS Device.NEWS2: Abbott Starts GUIDE-HF Clinical Trial for CardioMEMS Device.NEWS3: Abbott Starts GUIDE-HF Clinical Trial for CardioMEMS Device.NEWS4: How Eli Lilly’s Cardiovascular Products Performed in 4Q17.NEWS5: How Eli Lilly’s Cardiovascular Products Performed in 4Q17.NEWS6: Analysts’ Recommendations for Bristol-Myers Squibb in March 2018.NEWS7: Analysts’ Recommendations for Bristol-Myers Squibb in March 2018.

Answer: Rise